NCT03512756终止2 期
A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred
Tyme, Inc20 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2018年3月27日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 130
- 试验地点
- 20
- 主要终点
- Overall Survival (OS)
研究概览
简要总结
A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer participants who have failed two lines of prior systemic therapy. The trial is designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate.
(Part 1 enrollment complete) In the initial stage of the trial (36 participants), two dose levels of SM-88's metyrosine-derivative was evaluated.
(Part 2 actively enrolling) The second part will consist of a subsequent expansion of the trial to further assess safety and efficacy of SM-88 used with MPS containing the selected SM-88 RP2D from Part 1. A total of 250 participants in the second part will be randomized 1:1 either to the SM-88 arm (125 participants) or Physician's Choice of therapy for the Control Arm (125 participants). Participants should have previously received two lines of prior systemic therapy.
详细描述
Please refer to Inclusion/Exclusion Criteria and Summary
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Inclusion Criteria:
- •Biopsy-proven metastatic pancreatic adenocarcinoma with documented radiographic disease progression on or after one or more systemic therapies. Chemotherapy given as part of prior chemoradiation in the setting of non-metastatic pancreatic cancer does not count as a line of therapy. Chemotherapy given for at least 4 months as adjuvant after complete response is considered as a first line therapy.
- •Biopsy-proven metastatic pancreatic adenocarcinoma on or after two prior lines of systemic therapy. Chemotherapy given as part of prior chemo- radiation in the setting of non-metastatic pancreatic cancer does not count as a line of therapy unless metastases develop within 6 months of completing the chemo sensitization. Chemotherapy given for at least 4 months as adjuvant after a CR to any therapy (e.g. surgery and radiation therapy) is also considered as a first line therapy. Of the two prior lines, participants should have received a gemcitabine-based regimen for a prior line and a 5-FU based regimen as a prior line of therapy. Investigational therapies as part of a prior line regimen are permitted.
- •Participants Have received two (2) and not more than two (2) previous systemic regimens for the treatment of pancreatic adenocarcinoma
- •Must be eligible to receive one or more of the Physician Choice options.
- •Radiographically measurable disease of at least one site by CT scan (or MRI, if allergic to CT contrast media). Imaging results must be obtained within the 14-day window prior to randomization
- •Must have completed any investigational cancer therapy at least 30 days prior to first dose.
- •Must have completed any other cancer therapy at least 14 days prior to first dose and recovered from major side effects of prior therapies or procedures.
- •≥18 years of age.
- •Adequate organ function defined as follows (lab results must be obtained within the 7-day window prior to randomization):
- •All laboratory parameters ≤ Grade 2 NCI Common Terminology Criteria for Adverse Events (CTCAE) criteria.
- •In addition:
- •i. Hematologic: Platelets ≥ 100 x 109 g/dL; Absolute Neutrophil Count ≥ 1.5 x 109/L (without platelet transfusion or growth factors within the 7 days prior to the screening laboratory assessment).
- •ii. Hepatic: transaminase /alanine transaminase ≤ 2.5 x upper limit of normal (ULN); total or conjugated bilirubin ≤ 1.5 x ULN, alkaline phosphatase (ALP) < 2.5 x ULN.
- •iii. Renal: serum creatinine ≤1.5 x ULN and creatinine clearance ≥ 60 mL/min as calculated by the Cockroft-Gault method.
- •iv. Coagulation: International normalized ratio (INR) ≤ 1.2 within 28 days of starting study.
- •v. Albumin: ≥ 3.0 g/dL. vi. Weight: No more than a 5% change from Screening to Randomization (must be at least 1 week apart).
- •All acute toxic effects of any prior antitumor therapy resolved to Grade ≤ 1 before baseline, with the exception of alopecia and neurotoxicity (CTCAE Grade 1 or 2 permitted).
- •Able and willing to provide written informed consent to participate in this study.
- •12.Willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.
- •Must be able to swallow whole capsules.
- •Females must either be of non-reproductive potential, not breast-feeding or must have a negative urine or serum pregnancy test within 28 days of study treatment, confirmed prior to treatment on Day
- •Participant of fertile potential who engage in heterosexual intercourse with partners of childbearing potential must attest to the use of highly effective contraception while enrolled in the study and for at least 6 months following the last dose of study drug.
- •Highly effective birth control methods include the following (the participantshould choose 2 to be used with their partner):
- •Oral, injectable, or implanted hormonal contraceptives.
- •Condom with a spermicidal foam, gel, film, cream, or suppository.
- •Occlusive cap (diaphragm or cervical/vault cap) with a spermicidal foam, gel, film, cream, or suppository.
- •Or any one of the following:
- •Intrauterine device.
- •Intrauterine system (for example, progestin-releasing coil).
- •Vasectomized male (as determined by the investigator).
- •Tubal ligation/sterilization (female).
- •Exclusion criteria for Parts 1 and 2 are as follows:
- •Any screening laboratory, ECG, or other findings that, in the opinion of the investigator, medical monitor or the sponsor, indicate an unacceptable risk for the participant's participation in the study.
- •History or evidence of any clinically significant disorder, condition, or disease that, in the opinion of the investigator or medical monitor would pose a risk to the participant's safety or interfere with the study evaluations, procedures, or completion. Examples include intercurrent illness such as active uncontrolled infection, active or chronic bleeding event within 28 days of baseline, uncontrolled cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
- •History of a concurrent or second malignancy, except for adequately treated localized basal cell or squamous cell carcinoma of the skin, adequately treated superficial bladder cancer, adequately treated Stage 1 or 2 cancer currently in complete remission; or any other cancer that has been in complete remission for ≥ 5 years.
- •Participants with MSI-H pancreatic cancer who have not previously received pembrolizumab.
- •Any known actionable mutation (e.g. BRCA mutation) who have not been treated with an approved drug for the mutation (the drug does not have to be approved for the indication).
- •Radiation to all target lesions within 12 weeks of study baseline.
- •No measurable target lesions.
- •Current use, or up to 14 days prior use, of a restricted medication (see Section 8.7) or requires any of these medications during treatment phase.
- •Major surgery, defined as any surgical procedure that involves general anesthesia and a significant incision (i.e. larger than that required for placement of central venous access, percutaneous feeding tube, or biopsy) within 28 days of the first dose of study drug.
- •Minor surgical procedures within 7 days of baseline, or not yet recovered from any prior surgery.
- •Any dysphagia, odynophagia, esophageal dysmotility or stricture, known gastrointestinal (GI) malabsorption syndrome, or intractable diarrhea that may significantly alter the absorption of any of the components of SM-88 used with MPS, e.g., cirrhosis.
- •Known human immunodeficiency (HIV) virus infection. Note: HIV testing is not required in the absence of clinical suspicion.
- •Known hepatitis B surface antigen (HBsAg) positive.
- •Known hepatitis C (HCV) viral RNA present.
- •Have previously been enrolled in this study or any other study investigating SM-88 or who have previously received any SM-88, methoxsalen, phenytoin, or sirolimus in a clinical trial.
- •History of any known drug allergies to any study medication.
- •Are currently enrolled in, or have discontinued within 14 days of screening, from a clinical trial involving an investigational product or non-approved use of a drug or device.
- 另有 20 项未显示
排除标准
- 未提供
研究组 & 干预措施
Part 1 and Part 2 SM-88 Arm
Experimental
(Part 1 enrollment complete) SM-88 used with MPS (methoxsalen, phenytoin and sirolimus)
(Part 2 actively enrolling) SM-88 (920 mg per day) used with MPS (methoxsalen, phenytoin and sirolimus) will be administered to 125 evaluable participants until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met.
干预措施: SM-88 used with MPS (methoxsalen, phenytoin, sirolimus) (Drug)
Physician's Choice
Experimental
Physician's Choice therapy will be administered for a total of 125 evaluable participants until unacceptable toxicity, disease progression, or any of the treatment discontinuation criteria are met.
干预措施: Capecitabine, Gemcitabine, and 5-FU (Drug)
结局指标
主要结局
Overall Survival (OS)
时间窗: Up to 12 months
OS was defined as the number of days between the first study drug administration and death from any cause. Results are reported in weeks.
次要结局
- Progression Free Survival (PFS)(Up to 12 months)
研究者
研究点 (20)
Loading locations...
相似试验
终止
3 期
Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic CancerPancreatic CancerNCT01362582National Center for Tumor Diseases, Heidelberg32
终止
2 期
Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or AmpullaDuctal Adenocarcinoma of PancreasAdenocarcinoma of AmpullaNCT02626520Essentia Health11
已完成
2 期
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas CarcinomaResectable Prancreas CarcinomaNCT02172976Krankenhaus Nordwest40
尚未招募
3 期
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.Pancreatic AdenocarcinomaNCT04835064Fudan University600
终止
2 期
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic CancerPancreatic CancerNCT04258150Herlev Hospital26